<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30620" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Triptans</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nicolas</surname>
            <given-names>Samar</given-names>
          </name>
          <aff>MCPHS University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nicolas</surname>
            <given-names>Diala</given-names>
          </name>
          <aff>Steward St. Elizabeth's Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samar Nicolas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Diala Nicolas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30620.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Triptans comprise a class of medications approved by the US Food and Drug Administration (FDA) as the first-line agent for treating acute migraine episodes with or without aura. In the United States, 7 triptans are available in diverse dosage formulations, including sumatriptan, naratriptan, zolmitriptan, rizatriptan, almotriptan, frovatriptan, and eletriptan. Sumatriptan, in its subcutaneous formulation, is also approved for treating cluster headaches. Almotriptan has an FDA indication for use in adolescents for treating migraines lasting at least 4 hours. The FDA has also approved zolmitriptan nasal spray for children aged 12 or older and&#x000a0;rizatriptan for children aged 6 to 17.&#x000a0;Frovatriptan, naratriptan, and oral zolmitriptan have off-label uses for preventing menstrual migraine.</p>
        <p>When triptans bind to the neurogenic and central 5-serotonin receptors, they inhibit the release of vasoactive neuropeptides by inhibiting trigeminal nerve activation and blocking the transmission of pain signals to the brain. The binding of triptans to the vascular 5-HT1B receptors leads to vasoconstriction of the cranial arteries, which painfully dilate during a migraine attack. This activity reviews the indications, mechanisms of action, adverse event profile, and contraindications of different triptans as essential components in migraine therapy. This activity involves participating clinicians reviewing the best practice collaboration among primary or emergency care and consulting neurologists to enhance patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients who are appropriate candidates for triptan therapy based on established migraine diagnosis and severity.</p></list-item><list-item><p>Screen patients for contraindications to triptan therapy, including but not limited to severe hepatic or renal impairment, cardiovascular disease, and uncontrolled hypertension.</p></list-item><list-item><p>Select the most suitable triptan formulation and dosage for each patient based on their preferences, tolerability, and treatment goals.</p></list-item><list-item><p>Collaborate&#x000a0;with other healthcare providers to discuss the benefits, risks, and proper use of triptan therapy with patients, thereby optimizing triptan therapy and comprehensive migraine management.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30620&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30620">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30620.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Triptans comprise a class of medications approved by the US Food and Drug Administration (FDA) as the first-line agent for treating acute migraine episodes with or without aura.<xref ref-type="bibr" rid="article-30620.r1">[1]</xref><xref ref-type="bibr" rid="article-30620.r2">[2]</xref>&#x000a0;In the United States, 7 triptans are available in diverse dosage formulations, including sumatriptan, naratriptan, zolmitriptan, rizatriptan, almotriptan, frovatriptan, and eletriptan.<xref ref-type="bibr" rid="article-30620.r3">[3]</xref></p>
        <p>In the subcutaneous (SQ) formulation, sumatriptan is also approved to treat cluster headaches.<xref ref-type="bibr" rid="article-30620.r1">[1]</xref> Almotriptan has an FDA indication for use in adolescents for treating migraines lasting at least 4 hours.<xref ref-type="bibr" rid="article-30620.r4">[4]</xref> Zolmitriptan nasal spray is FDA-approved for children aged 12 or older.<xref ref-type="bibr" rid="article-30620.r5">[5]</xref><xref ref-type="bibr" rid="article-30620.r4">[4]</xref> Rizatriptan is an FDA-approved triptan for children aged 6&#x000a0;to 17.<xref ref-type="bibr" rid="article-30620.r6">[6]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Frovatriptan, naratriptan, and oral zolmitriptan have an off-label indication for preventing menstrual migraine.<xref ref-type="bibr" rid="article-30620.r7">[7]</xref><xref ref-type="bibr" rid="article-30620.r8">[8]</xref>&#x000a0;According to the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association, sumatriptan&#x000a0;can be used for acute attacks of cyclic vomiting syndrome.<xref ref-type="bibr" rid="article-30620.r9">[9]</xref></p>
      </sec>
      <sec id="article-30620.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Three distinct mechanisms of action of triptans have been described in migraine, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Vascular mechanism: Vasoconstriction of painfully distended intracranial extracerebral arteries directly affects vascular smooth muscle.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Trigeminovascular mechanism: Inhibition of nociceptive neurotransmission within the trigeminal nerve in the brainstem and upper spinal cord.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Central mechanism: Inhibition of the release of vasoactive neuropeptides by trigeminal nerve innervating the intracranial vessels and dura mater.<xref ref-type="bibr" rid="article-30620.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Triptans&#x000a0;are antimigraine agents&#x000a0;that bind to 5-HT1B and 5-HT1D serotonin receptors. Triptan binding to the vascular 5-HT1B receptors leads to vasoconstriction of the cranial arteries, which dilate during a migraine attack. When triptans bind to the neurogenic and central 5-HT1D receptors, they prevent the release of vasoactive neuropeptides by inhibiting trigeminal nerve activation and blocking the transmission of pain signals to the central nervous system.<xref ref-type="bibr" rid="article-30620.r10">[10]</xref></p>
        <p>
<bold>Salient Pharmacokinetics of Triptans</bold>
</p>
        <p>The pharmacokinetics of triptans vary widely between individuals, which could be attributed to the influence of P-glycoprotein (P-gp) efflux transporters, triptan-metabolizing enzymes, such as cytochrome P450 (CYP450) and monoamine oxidase (MAO), and drug bioavailability.<xref ref-type="bibr" rid="article-30620.r11">[11]</xref></p>
        <p><bold>Sumatriptan</bold>: Sumatriptan is available as oral tablets, nasal sprays, and SQ injections. Orally administered sumatriptan has a low bioavailability of around 15%, primarily due to pre-systemic metabolism and partly due to incomplete absorption. Despite nasal sprays being faster than oral formulations, their effect is more temporary. Therefore, nasal sprays are an intermediate option for oral triptans and SQ sumatriptan.&#x000a0;</p>
        <p>In vitro&#x000a0;studies on human microsomes suggest that the MAO enzyme metabolizes sumatriptan and, thus, is prone to serotonin syndrome when administered with other serotonergic drugs.&#x000a0;The elimination half-life (<italic toggle="yes">t</italic><sub>1/2</sub>) of sumatriptan is approximately 2.5 hours. A recent&#x000a0;study suggests that CYP1A2, CYP2C19, and CYP2D6 may be involved in the metabolism of sumatriptan. However, these findings require significant additional research.<xref ref-type="bibr" rid="article-30620.r12">[12]</xref>&#x000a0;</p>
        <p><bold>Rizatriptan</bold>: Rizatriptan has the fastest onset of action among orally administered triptans (approximately 30 minutes) but with short <italic toggle="yes">t</italic><sub>1/2</sub>&#x000a0;of 2&#x000a0;to 2.5 hours. This drug has the highest recurrence rate at 24 hours (superior to placebo). Hence, rizatriptan&#x000a0;is the better option when attacks are severe with rapid onset but are short-lasting.&#x000a0;The primary route of rizatriptan metabolism is by MAO-A, which forms the indole acetic acid metabolite. The metabolite is not active at the 5-HT1B/1D&#x000a0;receptor. Approximately 14% of an oral rizatriptan dose is excreted in urine as unchanged, while 51% is excreted as indole acetic acid metabolite, proving substantial first-pass metabolism.<xref ref-type="bibr" rid="article-30620.r13">[13]</xref></p>
        <p><bold>Frovatriptan</bold>: The onset of action is delayed, but&#x000a0;frovatriptan has the longest half-life of approximately 26 hours and the lower recurrence rate at 24 hours (7% to 25%).&#x000a0;Frovatriptan is&#x000a0;preferred&#x000a0;in long-lasting attacks of migraine. In addition, frovatriptan is not an inhibitor of human MAO enzymes. Frovatriptan is metabolized by CYP1A2. Renal clearance accounted for about 40% and 45% of total clearance in males and females.<xref ref-type="bibr" rid="article-30620.r14">[14]</xref></p>
        <p><bold>Almotriptan</bold>:&#x000a0;The absolute bioavailability of almotriptan tablets is about 70%, with peak plasma levels occurring 1 to 3 hours after administration. Food does not affect pharmacokinetics. Almotriptan is the only triptan with an FDA indication for use in adolescents.&#x000a0;Almotriptan is metabolized through&#x000a0;2 major and 1 minor pathways. Significant routes of metabolism include MAO-mediated oxidative deamination (around 27% of the dose) and CYP450-mediated oxidation (CYP2D6 and CYP3A4), and the minor route of metabolism is flavin monooxygenase.<xref ref-type="bibr" rid="article-30620.r15">[15]</xref></p>
        <p><bold>Zolmitriptan</bold>: Zolmitriptan undergoes conversion to an active <italic toggle="yes">N</italic>-desmethyl metabolite via the enzymes CYP1A2 and MAO-A, with the metabolite concentrations being approximately two-thirds that of zolmitriptan. This metabolite has 2 to 6 times the potency of the parent compound at 5HT1B/1D&#x000a0;receptors, and the metabolite contributes a substantial portion of the overall effect.<xref ref-type="bibr" rid="article-30620.r16">[16]</xref></p>
        <p><bold>Naratriptan</bold>: Naratriptan is better in moderate but long-lasting attacks. Naratriptan is metabolized by CYP1A2 and MAO-A enzymes.<xref ref-type="bibr" rid="article-30620.r17">[17]</xref></p>
        <p><bold>Eletriptan</bold>: Eletriptan is preferred in severe, long-lasting attacks because of the drug's long half-life. Only 10% of eletriptan is&#x000a0;excreted by the kidney, about 80% is eliminated&#x000a0;by&#x000a0;CYP3A4, and 10% by CYP2D6.<xref ref-type="bibr" rid="article-30620.r18">[18]</xref>&#x000a0;Eletriptan is a P-gp substrate and&#x000a0;can be inhibited or induced by P-gp inhibitors or inducers.<xref ref-type="bibr" rid="article-30620.r19">[19]</xref></p>
      </sec>
      <sec id="article-30620.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Available Dosage Forms and Strengths</bold>&#x000a0;</p>
        <p>Triptans are available in multiple dosage forms,&#x000a0;including&#x000a0;oral tablets, orally disintegrating tablets, nasal sprays, and SQ injections.<xref ref-type="bibr" rid="article-30620.r3">[3]</xref>&#x000a0;Besides oral tablets,&#x000a0;several alternative formulations of triptans are available to accommodate patient preferences. Orally disintegrating tablets present a suitable choice for patients who are not experiencing vomiting.<xref ref-type="bibr" rid="article-30620.r20">[20]</xref> Nasal spray and SQ injection options are viable for patients encountering nausea and vomiting before oral absorption of the medication.<xref ref-type="bibr" rid="article-30620.r21">[21]</xref>&#x000a0;</p>
        <p>Patients&#x000a0;are&#x000a0;instructed to administer triptans at the first onset of the headache phase of a migraine attack, as their efficacy diminishes if taken during the aura phase before the onset of the headache.<xref ref-type="bibr" rid="article-30620.r22">[22]</xref>&#x000a0;The patient may repeat the dose after 2 hours, if necessary, but not exceeding more than twice a week. "Triptan-overuse headache" refers to a rebound headache that may arise from&#x000a0;using triptans for more than&#x000a0;10 days per month.<xref ref-type="bibr" rid="article-30620.r23">[23]</xref></p>
        <p>
<bold>Adult Dosages</bold>
</p>
        <p>The various formulations and dosages of several triptans are provided below.</p>
        <p><bold>Sumatriptan:&#x000a0;</bold>Sumatriptan is available in different formulations, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral tablets: 25 mg, 50 mg, and 100 mg</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nasal spray: 5 mg, 10 mg, and 20 mg</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nasal powder: 11 mg per nosepiece, with the usual recommended dose being 22 mg</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>SQ&#x000a0;injection: Single-dose prefilled syringe options of 4 mg and 6 mg</p>
          </list-item>
        </list>
        <p><bold>Rizatriptan:&#x000a0;</bold>Rizatriptan is available in 2 formulations, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral tablets: 5 mg and 10 mg</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Orally disintegrating tablets: 5 mg and 10 mg</p>
          </list-item>
        </list>
        <p><bold>Zolmitriptan:&#x000a0;</bold>Zolmitriptan is available in&#x000a0;the below-mentioned formulations.</p>
        <list list-type="bullet">
          <list-item>
            <p>Nasal spray: 2.5mg and 5 mg</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oral tablets: 2.5 mg and 5 mg</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Orally disintegrating tablets: 2.5 mg and 5 mg</p>
          </list-item>
        </list>
        <p><bold>Frovatriptan:</bold> Frovatriptan is available as an oral tablet form in a strength of&#x000a0;2.5 mg.</p>
        <p><bold>Eletriptan: </bold>Eletriptan is available as an oral tablet form with strengths of 20 and 40 mg.</p>
        <p><bold>Naratriptan:</bold>&#x000a0;Naratriptan is available as an oral tablet form with strengths of&#x000a0;1 and 2.5 mg.</p>
        <p><bold>Almotriptan:</bold>&#x000a0;Almotriptan is available as an oral tablet form with strengths of 6.25 mg and 12 mg.</p>
        <p>The choice of agent should be individualized. If a patient has no response to one of the triptans after&#x000a0;3 trials, increasing the dose, switching to a different dosage of the same agent, or another triptan should be considered.<xref ref-type="bibr" rid="article-30620.r23">[23]</xref> A nonsteroidal anti-inflammatory drug (NSAID) administered with a triptan targets a different mechanism and may be more effective than a triptan alone. Sumatriptan is available as an oral tablet form combined with the NSAID naproxen.<xref ref-type="bibr" rid="article-30620.r24">[24]</xref></p>
        <p>During a migraine attack, patients may experience decreased gastric motility, causing a delay in gastric emptying, which may affect the rate and extent of triptan absorption when administered orally. Metoclopramide, an antiemetic agent, exhibits prokinetic activity and is FDA-approved to treat gastric stasis. Metoclopramide can improve the inconsistent absorption of orally administered triptans when taken concomitantly. However, metoclopramide has a boxed warning because of the risk of adverse effects such as extrapyramidal symptoms and hyperprolactinemia. Alternatively, an injectable or nasal triptan formulation is an option, as these formulations bypass the gastrointestinal tract.<xref ref-type="bibr" rid="article-30620.r25">[25]</xref>&#x000a0;</p>
        <p>A post hoc analysis of&#x000a0;5 randomized placebo-controlled, double-blind clinical trials compared the efficacy of triptans at relieving nausea associated with migraines&#x000a0;2 hours after therapy.<xref ref-type="bibr" rid="article-30620.r26">[26]</xref> Patients received rizatriptan 10 mg, naratriptan 2.5 mg, zolmitriptan 2.5 mg, or sumatriptan 25, 50, or 100 mg. Rizatriptan showed a statistically significant improvement in nausea versus sumatriptan and naratriptan. Rizatriptan and zolmitriptan provided similar nausea relief.&#x000a0;To prevent menstrual migraine, the recommendation is to start frovatriptan or naratriptan&#x000a0;2 days before&#x000a0;menstruation&#x000a0;and continue for 5 to 7 days.<xref ref-type="bibr" rid="article-30620.r27">[27]</xref>&#x000a0;</p>
        <p>For patients presenting with acute migraine<bold>&#x000a0;</bold>in the emergency room or urgent care, triptans, chlorpromazine, prochlorperazine, metoclopramide, dihydroergotamine, and ketorolac are used. Among triptans, sumatriptan 6 mg&#x000a0;administered by the SQ route is preferred due to its superior efficacy.<xref ref-type="bibr" rid="article-30620.r28">[28]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment: </bold>Renal infractions have been reported with triptans, therefore their use should be approached with caution. Acetaminophen is the preferred option for treating migraines in individuals with renal impairment. Frovatriptan and zolmitriptan are suitable alternatives for patients with renal impairment, as they are eliminated through both hepatic and renal routes. However, dose reductions are necessary for other triptans in such cases.<xref ref-type="bibr" rid="article-30620.r29">[29]</xref></p>
        <p><bold>Hepatic impairment: </bold>Triptans are contraindicated in severe hepatic impairment. A dose reduction may be required for mild-to-moderate hepatic impairment.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Using triptans during pregnancy&#x000a0;does&#x000a0;not&#x000a0;increase the&#x000a0;risk of&#x000a0;major congenital malformations or prematurity. However, increased rates of spontaneous abortions are common.<xref ref-type="bibr" rid="article-30620.r30">[30]</xref>&#x000a0;Pregnancy registry and other studies indicate that this&#x000a0;sumatriptan may be a safe&#x000a0;treatment option for severe migraine in pregnancy. However, acetaminophen remains the drug of choice for pregnant patients.<xref ref-type="bibr" rid="article-30620.r31">[31]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>The&#x000a0;American Association of Pediatrics (AAP) guidelines and pregnancy registries suggest that&#x000a0;sumatriptan is compatible during lactation.<xref ref-type="bibr" rid="article-30620.r32">[32]</xref><xref ref-type="bibr" rid="article-30620.r33">[33]</xref>&#x000a0;A recent study&#x000a0;investigated&#x000a0;the transfer of triptans in human breast milk by estimating relative infant dose (RID). Results indicated&#x000a0;that eletriptan (0.6%), sumatriptan (0.7%), and rizatriptan (0.9%) had the lowest RID and&#x000a0;are&#x000a0;usually compatible with breastfeeding. Naratriptan had the highest RID (5%) and should be avoided.<xref ref-type="bibr" rid="article-30620.r34">[34]</xref></p>
        <p><bold>Pediatric patients: </bold>According to the American Academy of Neurology (AAN) and the American Headache Society (AHS) guidelines, the FDA has approved the use of rizatriptan for children aged&#x000a0;6 or older, sumatriptan/naproxen for children aged 12 or older, almotriptan for children aged 12 or older, and zolmitriptan nasal spray for children aged 12 or older&#x000a0;in pediatric populations.<xref ref-type="bibr" rid="article-30620.r35">[35]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>The use of triptans&#x000a0;is contraindicated in&#x000a0;older patients. Acetaminophen and other&#x000a0;NSAIDs&#x000a0;are used after liver and renal function assessment. According to the clinical presentation, patients should be screened for hypertension and other secondary causes of headaches, such as giant cell arteritis.<xref ref-type="bibr" rid="article-30620.r36">[36]</xref></p>
      </sec>
      <sec id="article-30620.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Triptans may cause nausea, dizziness, and coronary vasoconstriction.<xref ref-type="bibr" rid="article-30620.r37">[37]</xref>&#x000a0;The most common&#x000a0;adverse effects of triptans, such as paresthesia, flushing, tingling, neck pain, and chest tightness, are known as "triptan sensations." These adverse effects are most pronounced with&#x000a0;SQ triptan injections and may be less severe with&#x000a0;other formulations. Cardiovascular adverse effects such as arrhythmias, myocardial infarctions, and strokes are rare, occurring in less than 1% of patients.<xref ref-type="bibr" rid="article-30620.r3">[3]</xref></p>
        <p>The severity of adverse effects may differ among triptans.<xref ref-type="bibr" rid="article-30620.r38">[38]</xref><bold>&#x000a0;</bold>Sumatriptan-induced acute angle closure glaucoma, an ocular emergency, requires immediate treatment.<xref ref-type="bibr" rid="article-30620.r39">[39]</xref>&#x000a0;A post hoc analysis of&#x000a0;5 randomized placebo-controlled, double-blind clinical trials compared the rate of nausea associated with triptans.<xref ref-type="bibr" rid="article-30620.r26">[26]</xref> The incidence of nausea was similar among patients treated with rizatriptan 10 mg, naratriptan 2.5 mg, and sumatriptan 25 mg, 50 mg, or 100 mg.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ischemic colitis induced by sumatriptan, naratriptan, and&#x000a0;rizatriptan&#x000a0;has been reported.<xref ref-type="bibr" rid="article-30620.r40">[40]</xref><xref ref-type="bibr" rid="article-30620.r41">[41]</xref>&#x000a0;Triptans should not be prescribed&#x000a0;to patients with a history of ischemic bowel disease.<xref ref-type="bibr" rid="article-30620.r42">[42]</xref><xref ref-type="bibr" rid="article-30620.r43">[43]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Triptans should be discontinued for medication overuse headaches.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac evaluation is necessary for patients with cardiovascular risk factors, as triptans&#x000a0;are&#x000a0;contraindicated in patients with variant angina, Prinzmetal angina, or coronary vasospasm.<xref ref-type="bibr" rid="article-30620.r44">[44]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Splenic infarction has been reported with triptans.<xref ref-type="bibr" rid="article-30620.r45">[45]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Spinal cord infarction has been reported following the use of zolmitriptan.<xref ref-type="bibr" rid="article-30620.r46">[46]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sumatriptan-induced cranial nerve paresis has been reported.<xref ref-type="bibr" rid="article-30620.r47">[47]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Product labeling and analysis of the World Health Organisation (WHO) adverse drug reactions database suggest that triptan&#x000a0;use is associated with seizures.&#x000a0;One must&#x000a0;differentiate between triptan-induced seizures and migraine aura-triggered seizures.<xref ref-type="bibr" rid="article-30620.r48">[48]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Propranolol, commonly prescribed for migraine prophylaxis, has been found to elevate serum concentrations of rizatriptan. Consequently, patients taking propranolol should not exceed a rizatriptan dose of 5 mg.<xref ref-type="bibr" rid="article-30620.r49">[49]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Naratriptan, eletriptan, and frovatriptan undergo metabolism via CYP450 enzymes, leading to potential drug-drug interactions with oral contraceptives. Clinicians should exercise caution when prescribing these medications to patients using oral contraceptives.<xref ref-type="bibr" rid="article-30620.r50">[50]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eletriptan undergoes hepatic metabolism primarily via CYP3A4. Therefore, caution should be exercised when administering CYP3A4 inhibitors such as fluconazole, erythromycin, verapamil, and ketoconazole, as they can potentially elevate the plasma concentration of eletriptan.<xref ref-type="bibr" rid="article-30620.r51">[51]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30620.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Triptans can cause vasoconstriction of the coronary and limb arteries. Therefore, these drugs are contraindicated in patients with a history of coronary artery disease, myocardial infarction, cerebrovascular accidents, hemiplegic or basilar migraines, uncontrolled hypertension, and peripheral vascular disease.<xref ref-type="bibr" rid="article-30620.r2">[2]</xref>&#x000a0;Triptans should not be used in individuals who suffer from severe hepatic or renal failure or those aged 65 or older. Except for sumatriptan, all triptans are contraindicated in pregnancy and breastfeeding.<xref ref-type="bibr" rid="article-30620.r3">[3]</xref> Wolff-Parkinson-White syndrome&#x000a0;and arrhythmia associated with cardiac accessory conduction pathway disorders are contraindications as they can lead to life-threatening ventricular tachycardia and ventricular fibrillation.<xref ref-type="bibr" rid="article-30620.r52">[52]</xref><xref ref-type="bibr" rid="article-30620.r53">[53]</xref><bold>&#x000a0;</bold></p>
        <p>Triptans should not be administered with ergot alkaloids or&#x000a0;MAO&#x000a0;inhibitors.<xref ref-type="bibr" rid="article-30620.r7">[7]</xref>&#x000a0;Insufficient&#x000a0;data exist for triptans increasing the risk of serotonin syndrome either as monotherapy or in patients taking a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin-norepinephrine reuptake inhibitor (SNRI).<xref ref-type="bibr" rid="article-30620.r54">[54]</xref></p>
      </sec>
      <sec id="article-30620.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Clinicians should monitor for triptan-associated cardiovascular adverse effects in patients taking propranolol. Propranolol is often used for migraine prevention and decreases the metabolism of some triptans like almotriptan and rizatriptan by inhibiting their metabolism via the MAO-A pathway. Lowering the triptan dose or using a triptan that is not metabolized by the MAO-A pathway or other abortive migraine therapy is preferred for these patients.<xref ref-type="bibr" rid="article-30620.r55">[55]</xref><xref ref-type="bibr" rid="article-30620.r49">[49]</xref></p>
        <p>Other monitoring parameters include the degree of response to triptan therapy, migraine recurrence, and consistent response to the same triptan. Also, patients review monitoring for nausea, vomiting, sensitivity to light and/or noise, which may occur during a migraine attack, and ultimately improve&#x000a0;the ability to function.<xref ref-type="bibr" rid="article-30620.r7">[7]</xref>&#x000a0;Red flags should be monitored during acute treatment of migraine in the emergency department. Red flags such as fever, thunderclap headache, focal neurologic deficit, positional headache, and papilledema can point toward secondary&#x000a0;etiologies of headache.<xref ref-type="bibr" rid="article-30620.r56">[56]</xref></p>
      </sec>
      <sec id="article-30620.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Analysis of triptan overdose cases from the National Poison Data System showed a low risk of death. Symptoms of triptan overdose include increased blood pressure, tachycardia, and drowsiness.&#x000a0;The mortality rate increased with&#x000a0;multiple&#x000a0;medication exposures, including&#x000a0;benzodiazepine and tricyclic antidepressants. No antidote for triptan overdose exists, and the treatment is supportive.<xref ref-type="bibr" rid="article-30620.r57">[57]</xref></p>
      </sec>
      <sec id="article-30620.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A migraine is a prevalent headache condition lasting up to 72 hours if left untreated or inadequately managed. During a migraine attack, nausea and vomiting can accompany the headache, significantly impacting the patient's daily functioning.<xref ref-type="bibr" rid="article-30620.r58">[58]</xref>&#x000a0;Clinicians, including neurologists, need to exercise caution, as recent analysis indicates that a considerable number of patients with contraindications are still being prescribed triptans.<xref ref-type="bibr" rid="article-30620.r59">[59]</xref>&#x000a0;Effective patient education plays a pivotal role in successful migraine management strategies.<xref ref-type="bibr" rid="article-30620.r7">[7]</xref>&#x000a0;The clinical team must educate patients about potential migraine triggers, such as stress, irregular meals, sleep disturbances, alcohol consumption, specific foods, and menstruation. Encouraging patients to maintain a migraine diary can aid in identifying individual triggers. Establishing realistic expectations and treatment goals with the patient is crucial, particularly given that some migraine triggers are unavoidable.<xref ref-type="bibr" rid="article-30620.r60">[60]</xref></p>
        <p>Some pharmacological and non-pharmacological therapies are available for migraine prevention.<xref ref-type="bibr" rid="article-30620.r60">[60]</xref> Prophylactic treatment reduces migraine frequency and severity. Patients should use abortive therapy when a migraine attack occurs. The indication for triptans is abortive migraine therapy.<xref ref-type="bibr" rid="article-30620.r7">[7]</xref>&#x000a0;If the response to triptan therapy does not relieve symptoms, the healthcare team should verify that the patient takes the triptan as soon as the headache pain begins.<xref ref-type="bibr" rid="article-30620.r7">[7]</xref> Additional causes of triptan failure could be malabsorption or other patient-related factors. A trial of another triptan may be beneficial in these patients.<xref ref-type="bibr" rid="article-30620.r61">[61]</xref></p>
        <p>Although the risk of serotonin syndrome is low in patients&#x000a0;prescribed triptans or combined with an SSRI or SNRI,&#x000a0;clinicians should monitor for symptoms and signs of serotonin syndrome and are encouraged to report such cases to MedWatch.<xref ref-type="bibr" rid="article-30620.r54">[54]</xref>&#x000a0;The interprofessional healthcare team, including clinicians and pharmacists, should formally counsel patients administering triptans. Patients should take the triptan as soon as the migraine starts for the best results.<xref ref-type="bibr" rid="article-30620.r62">[62]</xref>&#x000a0;The healthcare team should identify patients with headaches due to triptan overuse, defined as taking triptans&#x000a0;10 or more days per month. All interprofessional healthcare team members, including nurses and pharmacists, should be empowered to communicate concerns to the prescriber for remediation, such as contraindications to triptans use, medication overuse, and adverse events.</p>
        <p>Finally, a patient-centered approach remains crucial in migraine management, encompassing both prophylactic and abortive treatments. Given the variability in patient responses, treatment necessitates individualization, with regular reassessment to consider any changes in therapy.<xref ref-type="bibr" rid="article-30620.r63">[63]</xref>&#x000a0;The optimal utilization of triptans for migraine treatment demands the collaboration of an interprofessional healthcare team comprising clinicians, specialists, mid-level practitioners, nurses, and pharmacists. Each member contributes their specialized knowledge and skills to improve patient outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-30620.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30620&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30620">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30620/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30620">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30620.s11">
        <title>References</title>
        <ref id="article-30620.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cady</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan: update and review.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>1503</fpage>
            <page-range>1503-14</page-range>
            <pub-id pub-id-type="pmid">16859433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Negro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koverech</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martelletti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.</article-title>
            <source>J Pain Res</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>515</fpage>
            <page-range>515-526</page-range>
            <pub-id pub-id-type="pmid">29563831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonaci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ghiotto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in migraine therapy.</article-title>
            <source>Springerplus</source>
            <year>2016</year>
            <volume>5</volume>
            <fpage>637</fpage>
            <pub-id pub-id-type="pmid">27330903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eiland</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>The use of triptans for pediatric migraines.</article-title>
            <source>Paediatr Drugs</source>
            <year>2010</year>
            <month>Dec</month>
            <day>01</day>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>379</fpage>
            <page-range>379-89</page-range>
            <pub-id pub-id-type="pmid">21028917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeage</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older.</article-title>
            <source>Paediatr Drugs</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">26747634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tepper</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Migraine in Children.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>1021</fpage>
            <page-range>1021-1022</page-range>
            <pub-id pub-id-type="pmid">28594120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belv&#x000ed;s</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pagonabarraga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kulisevsky</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Individual triptan selection in migraine attack therapy.</article-title>
            <source>Recent Pat CNS Drug Discov</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-81</page-range>
            <pub-id pub-id-type="pmid">19149716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuchman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Emeribe</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study.</article-title>
            <source>CNS Drugs</source>
            <year>2008</year>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>877</fpage>
            <page-range>877-86</page-range>
            <pub-id pub-id-type="pmid">18788838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkatesan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levinthal</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Tarbell</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Jaradeh</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hasler</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Issenman</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Sarosiek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stave</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Sharaf</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>BUK</given-names>
              </name>
            </person-group>
            <article-title>Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association.</article-title>
            <source>Neurogastroenterol Motil</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>31 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>e13604</fpage>
            <pub-id pub-id-type="pmid">31241819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sheftell</surname>
                <given-names>FD</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of the 5-HT1B/1D receptor agonists.</article-title>
            <source>Arch Neurol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>7</issue>
            <fpage>1084</fpage>
            <page-range>1084-8</page-range>
            <pub-id pub-id-type="pmid">12117355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soldin</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Mara</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Triptans in pregnancy.</article-title>
            <source>Ther Drug Monit</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-9</page-range>
            <pub-id pub-id-type="pmid">18223456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000f6;stges</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lehr</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Metabolism of sumatriptan revisited.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>e01051</fpage>
            <pub-id pub-id-type="pmid">36655303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masuo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagamori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Isozumi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakamichi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kanai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.</article-title>
            <source>Pharm Res</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>1233</fpage>
            <page-range>1233-1243</page-range>
            <pub-id pub-id-type="pmid">28361200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lionetto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Andr&#x000e9;s</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Negro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martelletti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>414</fpage>
            <page-range>414-23</page-range>
            <pub-id pub-id-type="pmid">27582896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McEnroe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Fleishaker</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2005</year>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-46</page-range>
            <pub-id pub-id-type="pmid">15762767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karjalainen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Backman</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-65</page-range>
            <pub-id pub-id-type="pmid">18816299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cozza</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Triptans.</article-title>
            <source>Psychosomatics</source>
            <year>2002</year>
            <season>Nov-Dec</season>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>502</fpage>
            <page-range>502-4</page-range>
            <pub-id pub-id-type="pmid">12444236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Alderman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>331</fpage>
            <page-range>331-337</page-range>
            <pub-id pub-id-type="pmid">29497279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Millson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>391</fpage>
            <page-range>391-404</page-range>
            <pub-id pub-id-type="pmid">11249525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000e1;inez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Casado</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gasc&#x000f3;n</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Optimal management of severe nausea and vomiting in migraine: improving patient outcomes.</article-title>
            <source>Patient Relat Outcome Meas</source>
            <year>2013</year>
            <month>Oct</month>
            <day>11</day>
            <volume>4</volume>
            <fpage>61</fpage>
            <page-range>61-73</page-range>
            <pub-id pub-id-type="pmid">24143125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gladstone</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gawel</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Newer formulations of the triptans: advances in migraine management.</article-title>
            <source>Drugs</source>
            <year>2003</year>
            <volume>63</volume>
            <issue>21</issue>
            <fpage>2285</fpage>
            <page-range>2285-305</page-range>
            <pub-id pub-id-type="pmid">14524731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olesen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hettiarachchi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>No effect of eletriptan administration during the aura phase of migraine.</article-title>
            <source>Eur J Neurol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>671</fpage>
            <page-range>671-7</page-range>
            <pub-id pub-id-type="pmid">15469451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinclair</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sturrock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Matharu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Headache management: pharmacological approaches.</article-title>
            <source>Pract Neurol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>411</fpage>
            <page-range>411-23</page-range>
            <pub-id pub-id-type="pmid">26141299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krymchantowski</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Jevoux</surname>
                <given-names>Cda C</given-names>
              </name>
            </person-group>
            <article-title>The experience of combining agents, specially triptans and non steroidal anti-inflammatory drugs, for the acute treatment of migraine - a review.</article-title>
            <source>Recent Pat CNS Drug Discov</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-4</page-range>
            <pub-id pub-id-type="pmid">18221225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Papapetropoulos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kori</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kedar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abell</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications.</article-title>
            <source>Cephalalgia</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>408</fpage>
            <page-range>408-15</page-range>
            <pub-id pub-id-type="pmid">23463252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Massiou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McCarroll</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Vandormael</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lines</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.</article-title>
            <source>Headache</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>754</fpage>
            <page-range>754-63</page-range>
            <pub-id pub-id-type="pmid">11576198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sullivan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bushnell</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Management of menstrual migraine: a review of current abortive and prophylactic therapies.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>376</fpage>
            <page-range>376-84</page-range>
            <pub-id pub-id-type="pmid">20697846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelfand</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room.</article-title>
            <source>Neurohospitalist</source>
            <year>2012</year>
            <month>Apr</month>
            <day>01</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>51</fpage>
            <page-range>51-59</page-range>
            <pub-id pub-id-type="pmid">23936605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cady</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Managing migraine by patient profile: role of frovatriptan.</article-title>
            <source>Patient Prefer Adherence</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>501</fpage>
            <page-range>501-10</page-range>
            <pub-id pub-id-type="pmid">27103792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Etwel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Olutunfese</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nickel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nulman</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>490</fpage>
            <page-range>490-501</page-range>
            <pub-id pub-id-type="pmid">25644494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bozzo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nordeng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Einarson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety of triptans for migraine headaches during pregnancy and breastfeeding.</article-title>
            <source>Can Fam Physician</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>537</fpage>
            <page-range>537-9</page-range>
            <pub-id pub-id-type="pmid">20547518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <collab>American Academy of Pediatrics Committee on Drugs</collab>
            <article-title>Transfer of drugs and other chemicals into human milk.</article-title>
            <source>Pediatrics</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>108</volume>
            <issue>3</issue>
            <fpage>776</fpage>
            <page-range>776-89</page-range>
            <pub-id pub-id-type="pmid">11533352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ephross</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.</article-title>
            <source>Headache</source>
            <year>2014</year>
            <season>Jul-Aug</season>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>1158</fpage>
            <page-range>1158-72</page-range>
            <pub-id pub-id-type="pmid">24805878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amundsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nordeng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fuskev&#x000e5;g</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Nordmo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sager</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Spigset</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>128</volume>
            <issue>6</issue>
            <fpage>795</fpage>
            <page-range>795-804</page-range>
            <pub-id pub-id-type="pmid">33730376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oskoui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holler-Managan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Potrebic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Licking</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sowell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Victorio</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gersz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Leininger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zanitsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yonker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Sep</month>
            <day>10</day>
            <volume>93</volume>
            <issue>11</issue>
            <fpage>487</fpage>
            <page-range>487-499</page-range>
            <pub-id pub-id-type="pmid">31413171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riggins</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ehrlich</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Episodic Migraine and Older Adults.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-335</page-range>
            <pub-id pub-id-type="pmid">35384586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Hern&#x000e1;ndez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marichal-Cancino</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>MaassenVanDenBrink</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villal&#x000f3;n</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Side effects associated with current and prospective antimigraine pharmacotherapies.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-41</page-range>
            <pub-id pub-id-type="pmid">29226741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Comparative tolerability of oral 5-HT1B/1D agonists.</article-title>
            <source>Headache</source>
            <year>2000</year>
            <season>Jul-Aug</season>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>521</fpage>
            <page-range>521-7</page-range>
            <pub-id pub-id-type="pmid">10940090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zormpas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Panos</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan dose increase-induced acute angle closure glaucoma in chronic migraine sufferer.</article-title>
            <source>Drug Ther Bull</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>8</issue>
            <fpage>125</fpage>
            <page-range>125-127</page-range>
            <pub-id pub-id-type="pmid">35393301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fonseka</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Kurchin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Rizatriptan-Induced Ischemic Colitis.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>55</volume>
            <issue>7</issue>
            <fpage>1008</fpage>
            <page-range>1008-9</page-range>
            <pub-id pub-id-type="pmid">25881718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alkhatib</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Gangotena</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Rizatriptan induced acute on top of chronic ischemic colitis.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>104</volume>
            <issue>10</issue>
            <fpage>2643</fpage>
            <page-range>2643-4</page-range>
            <pub-id pub-id-type="pmid">19806107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akbar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nissan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rangasamy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mudrovich</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Isolated naratriptan-associated ischemic colitis.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>410</fpage>
            <page-range>410-411</page-range>
            <pub-id pub-id-type="pmid">27695179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Umyarova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arulthasan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daoud</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Unusual Case of Ischemic Colitis Caused by Low-Dose Sumatriptan Therapy in a Generally Healthy Patient After Strenuous Physical Activity.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>e17125</fpage>
            <pub-id pub-id-type="pmid">34532167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acikel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kilic</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akdemir</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prinzmetal-variant angina in a patient using zolmitriptan and citalopram.</article-title>
            <source>Am J Emerg Med</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>257.e3</fpage>
            <page-range>257.e3-6</page-range>
            <pub-id pub-id-type="pmid">20159412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous splenic infarction associated with sumatriptan use.</article-title>
            <source>J Headache Pain</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>214</fpage>
            <page-range>214-6</page-range>
            <pub-id pub-id-type="pmid">16767537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vijayan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Spinal cord infarction during use of zolmitriptan: a case report.</article-title>
            <source>Headache</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">10759907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Novitskaya</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Cates</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bowes</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Vivian</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Triptans and third nerve paresis: a case series of three patients.</article-title>
            <source>Eye (Lond)</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>503</fpage>
            <page-range>503-505</page-range>
            <pub-id pub-id-type="pmid">27858938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hareem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pahlavanzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Monjazeb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anyanwu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Case report: An EEG captured case of migralepsy/migraine aura-triggered seizures.</article-title>
            <source>Front Neurol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>953224</fpage>
            <pub-id pub-id-type="pmid">36034309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sciberras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Smet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lowry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tomasko</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Olah</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Halpin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kari</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-76</page-range>
            <pub-id pub-id-type="pmid">11453892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathew</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Hettiarachchi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alderman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.</article-title>
            <source>Headache</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>962</fpage>
            <page-range>962-74</page-range>
            <pub-id pub-id-type="pmid">14511273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rolan</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Drug interactions with triptans : which are clinically significant?</article-title>
            <source>CNS Drugs</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>11</issue>
            <fpage>949</fpage>
            <page-range>949-57</page-range>
            <pub-id pub-id-type="pmid">23018546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munjal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brand-Schieber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Allenby</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Spierings</surname>
                <given-names>ELH</given-names>
              </name>
              <name>
                <surname>Cady</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10&#x000a0;mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">28251391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kirsten</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Triptan-induced torsades de pointes and ventricular fibrillation cardiac arrest: case report and review of the literature.</article-title>
            <source>Curr Drug Saf</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>236</fpage>
            <page-range>236-9</page-range>
            <pub-id pub-id-type="pmid">24909575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Sun-Edelstein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tietjen</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.</article-title>
            <source>Headache</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-99</page-range>
            <pub-id pub-id-type="pmid">20618823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demaagd</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The pharmacological management of migraine, part 2: preventative therapy.</article-title>
            <source>P T</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>480</fpage>
            <page-range>480-7</page-range>
            <pub-id pub-id-type="pmid">19750179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Do</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Remmers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schytz</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Schankin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Obermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gantenbein</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Schoonman</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Jan</month>
            <day>15</day>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>134</fpage>
            <page-range>134-144</page-range>
            <pub-id pub-id-type="pmid">30587518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robblee</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System.</article-title>
            <source>Neurology</source>
            <year>2020</year>
            <month>Apr</month>
            <day>07</day>
            <volume>94</volume>
            <issue>14</issue>
            <fpage>e1460</fpage>
            <page-range>e1460-e1469</page-range>
            <pub-id pub-id-type="pmid">31792093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boisselle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guthmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cable</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical inquiry. What clinical clues differentiate migraine from sinus headaches? Pulsatile quality, duration of 4 to 72 hours, unilateral location, nausea or vomiting, and disabling intensity.</article-title>
            <source>J Fam Pract</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>62</volume>
            <issue>12</issue>
            <fpage>752</fpage>
            <page-range>752-4</page-range>
            <pub-id pub-id-type="pmid">24340338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhamoon</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Triptan medication use among patients with migraine with contraindications in the US.</article-title>
            <source>Headache</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>62</volume>
            <issue>7</issue>
            <fpage>883</fpage>
            <page-range>883-889</page-range>
            <pub-id pub-id-type="pmid">35670141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marmura</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Triggers, Protectors, and Predictors in Episodic Migraine.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <day>05</day>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>81</fpage>
            <pub-id pub-id-type="pmid">30291562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Triptan nonresponder studies: implications for clinical practice.</article-title>
            <source>Headache</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>156</fpage>
            <page-range>156-62</page-range>
            <pub-id pub-id-type="pmid">15705122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baron</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lettich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hastriter</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lovell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kalidas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
              <collab>American Headache Society Headache Fellows Research Consortium</collab>
            </person-group>
            <article-title>Triptan education and improving knowledge for optimal migraine treatment: an observational study.</article-title>
            <source>Headache</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>686</fpage>
            <page-range>686-97</page-range>
            <pub-id pub-id-type="pmid">24520930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30620.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diamond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cady</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care.</article-title>
            <source>Am J Med</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>118 Suppl 1</volume>
            <fpage>18S</fpage>
            <page-range>18S-27S</page-range>
            <pub-id pub-id-type="pmid">15841884</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
